-
MabSpace granted FDA Approval for MSB2311 IND
biospectrumasia
March 01, 2018
MabSpace Biosciences Announces FDA Approval of IND for MSB2311, a Second Generation PD-L1 Antibody With pH Dependent Antigen Binding and Recycling Property
-
CStone files CS1003, an anti-PD-1 antibody, for clinical trial approval in Australia
prnasia
December 29, 2017
CStone announced today that it has formally applied for clinical trial approval of the anti-PD-1 monoclonal antibody (mAb) candidate submitted to the Human Research Ethics Committee at the Scientia Clinical Research Center in Australia CS1003.
-
Novel bi-specific antibody shows strong therapeutic potential to treat Zika virus infection
biospectrumasia
October 13, 2017
Antibody works by neutralizing multiple strains of virus, thus preventing viral escape
-
Glythera and IONTAS to collaborate for development of multiple antibodies for next-generation Antibo
pharmaasia
September 26, 2017
This collaboration will capitalise on the Glythera ADC development expertise and Iontas' experience in antibody discovery services for optimal effect.
-
Ligand to receive US$2mn from WuXi Biologics for licensing antibody
pharmaasia
August 23, 2017
Ligand is also entitled to future milestones and royalties from this antibody.
-
HIV vaccine to come?! Play without scruple from now on? No!!!
en-cphi.cn
August 18, 2017
The news of an HIV vaccine appROACH in development titled J & J announced 100% production of antibody has flooded the websites.
-
Suptavumab Does Not Meet Primary Endpoint
americanpharmaceuticalreview
August 15, 2017
Regeneron Pharmaceuticals announced a Phase 3 study evaluating suptavumab (REGN2222), an antibody to respiratory syncytial virus (RSV), did not meet its primary endpoint of preventing medically-attended RSV infections in infants.
-
Frontier Biotech licenses 3BNC117, a novel broad-spectrum HIV neutralizing antibody
en-cphi.cn
July 26, 2017
Frontier Biotechnologies, Inc. announced it has signed an agreement with The Rockefeller University of the US for the worldwide license for combining 3BNC117...
-
Aptevo, Alligator in Bispecific Antibody Development Pact
contractpharma
July 24, 2017
Aptevo Therapeutics Inc. and Alligator Bioscience have entered into an agreement to co-develop an immunotherapy bispecific antibody candidate, ALG.APV-527, based on Alligator’s first generation bispecific antibody, ATOR-1016.
-
Bioconjugation specialist Innova Biosciences acquired by SYGNIS
cphi-online
June 29, 2017
Innova’s range of antibody and protein labeling products and services ideally complements SYGNIS’ customer base and existing genomics and proteomics portfolio.